Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma  

作　　者：Zhengxin Wang Jiayin Yang Guangming Li 

机构地区：[1]Liver Transplantation Center,General Surgery Department,Huashan Hospital Affiliated to Fudan University,Organ Transplantation Institute of Fudan University,Shanghai 200040,China [2]Organ Transplantation Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610044,China [3]Liver Transplantation Center,General Surgery Department of Beijing Youan Hospital,Capital Medical University,Beijing 100069,China

出　　处：《Chinese Medical Journal》2024年第18期2143-2145,共3页中华医学杂志（英文版）

基　　金：funded by the National Key Research and Development Program of China(Nos.2021YFA1100500 and 2023YFC2505900);National Natural Science Foundation of China(Nos.81873874,82071797,and 82241225);Beijing Natural Science Foundation(No.7222096)

摘　　要：Primary liver cancer(PLC)is the fourth-most common malignancy and second leading cause of tumor-related deaths in China.Hepatocellular carcinoma(HCC)accounts for 75-85%of PLCs.[1]At present,radical surgery remains the most effective treatment option for HCC,including liver resection and liver transplantation(LT).The indications of LT for HCC are relatively strict because of a shortage of donor livers and the risk of postoperative tumor recurrence and metastasis.Patients with tumor burdens exceeding LT criteria may undergo downstaging treatment to meet the criteria.In recent years,new drugs for HCC have been continuously developed.Among them,systemic therapeutic drugs represented by molecular targeted drugs and immune checkpoint inhibitors(ICIs)have created a new era in the treatment of HCC.

关 键 词：DRUGS treatment EXCEEDING 

分 类 号：R735.7[医药卫生—肿瘤]